ECOG-ACRIN Cancer Research Group

ICYMI: Check out our round-up of recently published @eaonc.bsky.social and @precogonc.bsky.social research results. More here ➡️ bit.ly/july25research

#ClinicalTrials #BreastCancer #CancerControl #CancerSurvivorship #HeadandNeck #LungCancer #Melanoma

An encouraging update from Washington re: support for #CancerResearch funding! Good news for the entire cancer research community--but most importantly for patients.

#FindingsFriday: Did you know we publish patient-friendly, 1-2 page summaries of the results of many of our #ClinicalTrials? View them here: bit.ly/trial-summar... #CancerResearch #ClinicalTrials

Trial Spotlight: Ken Cardona Gives an Update on the EA7211/STRASS 2 Sarcoma Trial In Sarcoma Cancer Awareness Month, we highlight a clinical trial for patients with this rare cancer, which has had few treatment advances

#RareCancers like #sarcoma can be difficult to study--but cooperative research groups like ours make it possible. This #SarcomaAwarenessMonth, learn about EA7211/STRASS 2, an international trial in #RetroperitonealSarcoma: bit.ly/EA7211STRASS... @eortc.org

Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer

Great work to Atlantic Health System for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM

Do you have an aggressive B-cell #Lymphoma that has either come back or persisted after initial therapy? If so, you may be eligible to participate in #ClinicalTrial EA4231. More info here: bit.ly/EA4231 #lymsm

Read more from our co-chairs on the importance of protecting public support for biomedical research: bit.ly/3IvxNQD #CancerResearch #ClinicalTrials

Today is #GBMDay! 🧠 Learn about EAF223/GABLE, a #Glioblastoma study testing different imaging techniques that could help make better predictions about #BrainCancer progression. Learn more here: bit.ly/gable-trial

Did you know July is #SarcomaAwarenessMonth? Take a moment to read our trial spotlight on EA7211/STRASS 2. This #clinicaltrial is the second randomized study ever performed in retroperitoneal soft tissue #sarcoma. More: bit.ly/EA7211STRASS...

Now Enrolling: EA5231/CLEAR Study for Patients With Operable Non-Small Cell Lung Cancer This clinical trial aims to improve survival for high-risk patients by adding a targeted therapy to standard post-surgery immunotherapy

Now Enrolling: CLEAR Study for Operable Non-Small Cell Lung Cancer blog-ecog-acrin.org/now-enrollin...

In #ClinicalTrial EA7222, investigators are testing doxorubicin plus pembrolizumab vs. doxorubicin alone for patients with advanced undifferentiated pleomorphic sarcoma (UPS). For more information: bit.ly/EA7222 #sarcomaawareness

Congratulations to Dr. Petros Grivas on receiving the 2025 Young Investigator Award from @eaonc.bsky.social! He's recognized for a distinguished record of innovative research, outstanding clinical practice, and unwavering dedication to advancing the field of genitourinary oncology.

In the latest edition of our advocacy blog, Glenn Sykes, #KidneyCancer survivor and #CancerResearch advocate, writes about the importance of a strong patient-oncologist bond. In honor of #NationalCancerSurvivorsMonth, read more: bit.ly/44Vobb4

Grivas, Schiller, Avigan receive ECOG-ACRIN 2025 scientific leadership, mentorship awards - The Cancer Letter Petros Grivas, Joan Schiller, and Zachary Avigan were named recipients of the ECOG-ACRIN Cancer Research Group annual scientific awards, which are funded by the ECOG Research & Education Foundation. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not […]

Petros Grivas of @fredhutch.bsky.social, Joan Schiller of @ouchinternational.bsky.social, and Zachary Avigan receive ECOG-ACRIN (‪@eaonc.bsky.social‬) 2025 scientific leadership, mentorship awards
https://cancerletter.com/in-brief/20250613_8b/

Institution Spotlight: Stanford Cancer Institute The Stanford Cancer Institute was founded in 2004 and builds on Stanford’s long history of cancer research, which started in 1956 when Henry Kaplan developed the linear accelerator. The institute is…

The Stanford Cancer Institute has been an @eaonc.bsky.social Cancer Research Group Main Member Institution since 1985. This membership reflects our leadership in national cancer research, helping shape and conduct NCI-sponsored clinical trials nationwide.  blog-ecog-acrin.org/institution-...

A phase II trial led by Dr. Barbara Burtness studying results of transoral surgery + risk-based adjuvant treatment in #HPV related #oropharyngealcancer showed surgery w/tailored postop treatment led to excellent outcomes.
ascopubs.org/doi/10.1200/...
@eaonc.bsky.social @yaleschoolofmed.bsky.social

Trial Spotlight: Helena Yu Gives an Update on the EA5182 Trial for EGFR-Mutant Non-Small Cell Lung Cancer This phase 3 randomized controlled trial is comparing first-line treatment with osimertinib plus bevacizumab versus osimertinib alone in patients with metastatic, EGFR-mutant non-small cell lung cance...

Great work to Houston Methodist Sugar Land Hospital for enrolling their first patient in #ClinicalTrial EA5182! This study is exploring osimertinib +/- bevacizumab as initial treatment for pts with EGFR-mutant #LungCancer. Learn more: bit.ly/3YHjYnZ #lcsm

If you are not registered, ECOG-ACRIN members can still sign up for access to the session recordings through this link: bit.ly/ea-spring25

If you are an ECOG-ACRIN member, the Spring 2025 Group Meeting session recordings are available on the Attendee Hub Website!

Log in with your first name, last name, and the email address you used during registration to view sessions you may have missed. cvent.me/Y5NW4q

Congratulations to Dr. Joan Schiller! Remarkable, indeed!

#ClinicalTrial EA6141 is testing combination therapy with ipilimumab, nivolumab, & sargramostim in advanced #melanoma. As May is #MelanomaAwarenessMonth, learn more about this important trial: bit.ly/ea6141melanoma #MelanomaAwareness

Powerful talk on building strong patient-oncologist relationships by #CancerResearch advocate and #KidneyCancer survivor Glenn Sykes during our Spring 2025 General Session. #EAOnc

Congratulations to the 2025 #EAOnc Remarkable Mentor in Oncology Award recipient, Dr. Joan Schiller of @lungcancerresearch.bsky.social @ouchinternational.bsky.social! #mentorship #LungCancer

Congratulations to Dr. Zachary Avigan of the Icahn School of Medicine at Mount Sinai on receiving the 2025 #EAOnc Paul Carbone, MD Fellowship Award! #CancerResearch #ClinicalTrials #MultipleMyeloma

Congratulations to @pgrivasmdphd.bsky.social of @uwmedicine.bsky.social @fredhutch.bsky.social on receiving the 2025 #EAOnc Young Investigator Award. Well deserved! #CancerResearch #ClinicalTrials #BladderCancer

This morning's #NCORP PI Committee Session was followed by a "Coffee and Protocols” poster discussion ☕️📈🩺#EAOnc

Inspiring advice from keynote speaker Dr. Efrat Dotan of @pennmedicine.bsky.social @pc3innovation.bsky.social at our Spring 2025 Task Force on #CareerAdvancement Session: 1) have an open mind, 2) learn from failures, and 3) develop relationships with colleagues

Many thanks to the esteemed presenters and panelists who participated in this spring's Robert L. Comis, MD #TranslationalScience Symposium: Dr. Charu Aggarwal, Dr. Dustin Deming, Dr. Gad Getz, Dr. Barbara Burtness, & our excellent moderator Dr. David Mankoff!

The Comis #TranslationalScience Symposium continues with talks on circulating marker technology by Dr. Gad Getz of @broadinstitute.org and integrating circulating markers into #ClinicalTrial design by Dr. Dustin Deming of @uwmadison.bsky.social and @uwhealth.bsky.social.

The Spring 2025 Robert L. Comis, MD #TranslationalScience Symposium has officially kicked off with a great talk by Dr. Charu Aggarwal of @penncancer.bsky.social @pc3innovation.bsky.social on Tumor-Informed and Tumor Uninformed #ctDNA Approaches for Minimal Residual Disease (#MRD) Detection.